Antiva Biosciences Closes $31 Million Series D Equity Financing

SOUTH SAN FRANCISCO, Calif.: SOUTH SAN FRANCISCO, Calif., Nov. 2, 2021 /PRNewswire/ -- Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today announced the closing of a $31 million Series D equity financing. The financing was...

Click to view original post